The BRAF p.V600E mutation was detected in two of our cases, similarly to the previously reported studies.2, 32, 37 Although the overall percentage of SDCs with mutated BRAF may be low, there is a potential for targeted therapy for these patients, as BRAF inhibitors are used successfully in melanoma and other BRAF‐mutated tumors. This evidence concerns the gene BRAF and melanoma.